Skip to main content

Table 2 Antimicrobial susceptibility of S. pneumoniae as classified by CLSI and EUCAST §

From: Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Antimicrobial agenta(n° of strains) CLSI susceptibility breakpoint (mg/L) EUCAST susceptibility breakpoint(mg/L) CLSI %S EUCAST %S Type of discrepancyb
Benzyl-penicillin (37.642) 2*c 1** 94.2 87.4 minor
Amoxicillin-clavulanate (2725) 2 0.5*** 99.2 87.6 major
Cefaclor (2.581) 1 0.032 92.3 0.5 very major
Cefpodoxime (5.725) 0.5 0.25 84.1 82.5 minor
Cefuroxime axetil (32.729) 1 0.25 79.6 73.6 minor
Cefotaxime (12.800) 1c 0.5 99.3 97.6 minor
Ceftriaxone (3.138) 1c 0.5 98.4 89.7 minor
Meropenem (575) 0.25c 2 97.7 99.8 minor
Ertapenem (3.680) 1 0.5 99.7 99.0 -
Imipenem (1.643) 0.12 2 95.4 99.9 minor
Moxifloxacin (26.746) 1 0.5 98.5 98.4 -
Ofloxacin (4.412) 2 0.125 95.4 0.0 very major
Azithromycin (63.481) 0.5 0.25 69.1 68.8 -
Telithromycin (7.034) 1 0.25 99.4 95.9 minor
Clindamycin (38.126) 0.25 0.5 81.4 81.6 -
Vancomycin (51.053) 1 2 99.8 100 -
  1. § CLSI [11] and EUCAST [13].
  2. aFor Cefuroxime parenteral, Levofloxacin, Erythromycin and Clarithromycin, CLSI and EUCAST suggested the same susceptibility breakpoints.
  3. bDiscrepancy as defined in the materials and methods section.
  4. cBreakpoint refers to non meningeal infections.
  5. * breakpoint refers to a dosage of 2 million units 6 times daily.
  6. ** breakpoint refers to a dosage of 2.4 gm 4 times or 1.2 gm 6 times daily.
  7. *** breakpoint refers to Ampicillin. The rate of susceptibiliy to Amoxicillin-clavulanate has been inferred from the rate of susceptibility to Ampicillin.